Metastatic castration-sensitive prostate cancer (MSK, Clin Cancer Res 2020)

Summary

Metastatic castration-sensitive prostate cancer (MSK, Clin Cancer Res 2020) is a study catalogued by cBioPortal DataHub under the cancer-type code prad. EvidenceHelix groups it with prostate studies.

Study description

MSK-IMPACT sequencing of 424 matched tumor-normal samples from patients with metastatic castration-sensitive prostate cancer. Germline alterations are not shown here.

Text as published in the source's study metadata.

Citation & PubMed

Stopsack et al. Clin Cancer Res 2020

Linked PubMed records: PMID 32220891

Source & licence

Metadata from cBioPortal DataHub at e1b75cd25b, available under the ODC Open Database License (ODbL) 1.0. See the Source metadata tab for every field.

Source metadata

Study identifier

prad_mcspc_mskcc_2020

Short name

PRAD_MCSPC (MSK, CCR 2020)

Source cancer-type code

prad

Reference genome

not given

Source access groups

PUBLIC

Original study

View on cBioPortal

Metadata file

meta_study.txt at e1b75cd25b

Database licence

ODC Open Database License (ODbL) 1.0

Study-level metadata only (title, description, cancer-type code, citation, PubMed ids). No patient, sample, mutation or clinical data, and no publication full text, is included. Individual studies may carry their own terms; follow each study's source links before reusing its data.

Citations

Stopsack et al. Clin Cancer Res 2020

• PubMed record 32220891 ↗

Citation counts are not part of the source metadata and are not shown.

Related studies

• Prostate Adenocarcinoma (MSK, Cancer Cell 2010)

  Comprehensive profiling of 218 prostate tumors (181 primaries, 37 metastases) and 14 prostate cancer cell lines and xenografts. MSKCC Prostate Oncogenome Project. Normalized flat data files (http://cbio.mskcc.org/canc…

  ProstateMSK studiesSource code pradPubMed 1

• Prostate Adenocarcinoma (MSK, Clin Cancer Res. 2022)

  Targeted sequencing of 1417 Prostate Adenocarcinoma tumor/normal sample pairs via MSK-IMPACT to analyze the significance of PIK3R1 alterations.

  ProstateMSK studiesSource code pradPubMed 1

• Prostate Adenocarcinoma (MSK, Eur Urol 2020)

  Targeted sequencing of 1465 prostate adenocarcinoma tumor/normal pairs via MSK-IMPACT.

  ProstateMSK studiesSource code pradPubMed 1

• Prostate Adenocarcinoma (MSK, PNAS 2014)

  Genome-wide copy number profiling in 104 primary prostate cancer tumor/normal pairs. Raw data via GEO (GSE54691) (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE54691).

  ProstateMSK studiesSource code pradPubMed 1

• Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)

  Whole exome Sequencing of 1013 prostate cancer samples and their matched normals.

  ProstateMSK studiesSource code pradPubMed 1

• Prostate Adenocarcinoma Organoids (MSK, Cell 2014)

  Exome sequencing of 12 advanced prostate cancer samples and matched organoids

  ProstateMSK studiesSource code pradPubMed 1

• Prostate Cancer (MSK, JCO Precis Oncol 2017)

  IMPACT sequencing of 504 prostate cancer tumor/normal pairs.

  ProstateMSK studiesSource code pradPubMed 1

• Prostate Cancer (MSK, Science 2022)

  Targeted sequencing and whole exome sequencing of 35 prostate cancer tumors, organoids and cell lines via MSK-IMPACT.

  ProstateMSK studiesSource code pradPubMed 1

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.